Skip to main content

Table 1 Table of ranges

From: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms

Cancer

N

Acceptable ranges

Protein 1

Protein 2

Protein 3

MW

(kDa)

pI

(pH)

MW

(kDa)

pI

(pH)

MW

(kDa)

pI

(pH)

Bladder

25

63–66

4.2–5.6

42–48

4.1–4.8

  

Blood cell (total)

88

34–47

3.5–4.5

    

Breast

538

64–69

4.2–4.9

    

Cervical

37

90–100

4.2–5.4

    

Colorectal

90

80–96

4.4–5.4

50–65

4.2–5.3

33–46

3.8–5.2

Endometrial (uterine)

60

67–71

4.2–5.1

41–48

3.7–5.4

  

Esophageal

9

42–47

4.6–5.2

    

Gastric

10

120–188

4.7–5.5

50–62

4.5–5.6

45–53

2.4–3.6

Hepatocellular

19

58–70

4.5–5.0

34–40

4.1–5.2

  

Kidney (renal cell)

21

69–73

4.7–5.4

54–61

4.1–5.2

38–43

3.7–4.3

 Leukemiaa

32

34–45

3.5–4.5

    

Lung (total)

103

52–56

4.1–5.3

    

 Lung, non-small cella

71

54–56

4.7–5.3

    

 Lung, small-cella

32

52–53

4.1–4.6

    

 Lymphomaa

33

43–45

3.5–4.5

    

Melanoma

39

37–41

4.6–5.3

    

Mesothelioma

25

60–68

3.8–4.1

38–44

3.8–4.6

  

 Myelomaa

23

38–47

3.6–4.5

    

Ovarian

102

72–90

3.7–5.0

37–47

3.7–5.0

  

Pancreatic

62

48–51

3.9–5.4

    

Prostate

182

71–88

5.1–6.5

    

Sarcoma

22

50–55

5.2–5.6

37–45

4.3–4.9

  

Squamous cell

46

57–68

5.0–5.4

    

Testicular germ cell

5

61–62

5.0–5.4

42–45

4.4–4.7

  

Thyroid follicular

14

48–56

4.7–5.1

37–42

4.5–5.2

  

Thyroid papillary

22

56–67

4.5–5.0

37–44

3.2–3.6

  

Totals

1519

      
  1. aBracketed entries are aggregate cancers or subsets already represented in the totals as aggregates (lung) or subsets (blood cell cancers)